PepDiana
Back to Evidence
Primary experimental recordPositive observation

PMC12935919::ACT037549

Myoki

Evidence text

Paper-level observation

Section 3.2 / Figure 3B: 'the Day 6 fusion index increased from 22.54% ± 3.42% in the control group to ... 35.16% ± 3.97% in the Myoki-treated groups'.
textConfidence: medium

Assay observation

Activity
Metabolic/Cardiovascular
Subtype
Other
Measure
other
Comparator
=
Raw observation
35.16% ± 3.97% (percent)
Normalized measurement
=35.16%
Value minimum
Not reported by source
Value maximum
Not reported by source
Target
Mus musculus
Assay method
Not reported by source
Sequence
EAEYEHL
Standardization
ready simple

Source publication

The therapeutic potential of Myoki, a novel peptide in muscle atrophy: mechanisms and applications.

Frontiers in Pharmacology · 2026

DOI 10.3389/fphar.2026.1663850 PMC12935919
Parent mention

Related peptide identities

PEPDIA-PLP-000522

Release PepDiana-V1-20260620. The stable record URL can be cited directly in supplementary material and downstream analyses.